person
Myriam C.
- Country
- The Netherlands
- Department
- Department of Biometrics
Research Overview
assignment
11
Clinical Trials ·
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
- Phase 3 Randomized Study of Relatlimab-Nivolumab vs. Regorafenib or Trifluridine/Tipiracil in Late-Line Metastatic Colorectal Cancer
- Neoadjuvant Efficacy and Safety of Botensilimab and Balstilimab in dMMR and pMMR Tumors: A Pan-Tumor Basket Study
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
76
Sites with multiple studies
Has run more than one trial at 76 of 199 partner sites.
Specializations
Colorectal Cancer Research
The investigator specializes in innovative treatments for colorectal cancer, with particular emphasis on immunotherapy approaches. Their research encompasses both early-stage and metastatic disease conditions.
- Neoadjuvant immunotherapy for colon cancer
- Advanced metastatic colorectal cancer treatments
- HER2-positive colorectal cancer therapies
- MSI-High colorectal cancer interventions
Gastric Cancer Studies
The investigator conducts research in gastric and gastroesophageal junction cancers, focusing on combination therapeutic approaches and surgical outcomes.
- Pre-operative combination therapies
- Neoadjuvant-adjuvant treatment strategies
- Resectable gastric cancer management
Specialized Cancer Pathways
The investigator explores specific molecular pathways and biomarkers in cancer treatment, with focus on mismatch repair deficiency and targeted therapies.
- dMMR tumor treatments
- Immune checkpoint inhibition
- Novel immunotherapy combinations
- Pan-tumor approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.